bilaterals.org logo
bilaterals.org logo

India FTAs & medicines


MSF statement on resumption of EU-India FTA negotiations
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
Delhi’s RCEP talks on intellectual property shouldn’t forget India’s role as ‘Pharmacy of the World’
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
India-Cambodia deliberates on financial support in agriculture, pharmaceuticals
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
FTA with Peru: India may have to lower import duty on drugs
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
Israel set to make a strong push for goods FTA
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
RCEP: India in a Catch-22
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
As India set to sign FTA with Peru, govt seeks industry views on export import duty rates
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
India to oppose anti-generics proposals at RCEP meet
India firm in opposing proposals that could hinder global access to affordable generic drugs
India will not cross red lines on generic drugs in RCEP, but stay vigilant, say officials
Healthcare watchers are calling on India to resist RCEP
Access to affordable stents and other medical devices – Indian Government should reject the bullying tactics of the US based medical device industry
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
RCEP negotiations should not restrict global access to affordable medicines and vaccines
Free trade talks with EFTA grouping hit IPR, services wall
Switzerland insists on intellectual property commitments beyond TRIPS.
Neelam Deo on EU-India’s perplexing relationship: Trade, Europe’s hypocrisy and China concern
Former diplomat says the EU’s insistence on opening up on wine imports from France and automobile imports from Germany have held up the EU-India FTA negotiations.
Big pharma, IP wars and profit over people
At RCEP negotiations held in India, intellectual property rights issues in medicine remain contentious
Interview with Loon Gangte
Loon Gangte is an Indian activist living with HIV and hepatitis C, founder of the Delhi Network of Positive People.
Trading health through IPR, patents
Trade agreements between countries have a perceivable impact on access to medicines as a result of changes in patent and other national laws in different countries.
MSF response on the India-EFTA free trade agreement negotiations in Liechtenstein this week
Through this deal, Swiss pharmaceutical corporations are working to erode India’s ability to produce and supply generic medicines for people across the developing world.
MSF response on RCEP negotiations in the Philippines
Negotiators must protect public health safeguards that enable developing countries like India to keep supplying life-saving affordable medicines for millions of people worldwide.
Stop trading workers’ rights over profits
RCEP magnifies existing inequalities and discriminates against women, indigenous peoples, people living with HIV or other illnesses, people with disabilities,rural communities, farmers and workers
Employment crisis and free trade agreements( FTAs) : Why workers should reject RCEP
Trade unions, farmers groups, health activists, and other people’s movements are planning to organise a series of events to put pressure on the Government of India to withdraw from RCEP negotiations.